Neurexis Therapeutics, Inc.
Publicly observedAurora, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Aurora | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Neurexis Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | H6VMU4FMUAF5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant17 Sept 2026Publicly observed
NIH SBIR/STTR award: Restoring AD-related neuronal dysfunction with a neuroprotective peptide
USD 484,929.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant15 Apr 2023Publicly observed
NIH SBIR/STTR award: Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
USD 299,550.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant24 Sept 2021Publicly observed
NIH SBIR/STTR award: IND-enabling studies for a potent and efficient neuroprotective drug
USD 238,126.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant24 Sept 2021Publicly observed
NIH SBIR/STTR award: IND-enabling studies for a potent and efficient neuroprotective drug
USD 1,833,347.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.